© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Artiva Biotherapeutics, Inc. (ARTV) stock declined over -1.89%, trading at $10.93 on NASDAQ, down from the previous close of $11.14. The stock opened at $11.33, fluctuating between $10.76 and $11.33 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | 11.33 | 11.33 | 10.76 | 10.93 | 198.31K |
| Aug 20, 2026 | 11.50 | 11.58 | 10.93 | 11.14 | 318.92K |
| Aug 19, 2026 | 11.69 | 11.85 | 11.21 | 11.70 | 457.49K |
| Aug 18, 2026 | 11.52 | 12.00 | 11.52 | 11.68 | 261.82K |
| Aug 17, 2026 | 11.45 | 11.84 | 11.10 | 11.74 | 288.56K |
| Aug 14, 2026 | 11.24 | 11.59 | 10.80 | 11.45 | 264.41K |
| Aug 13, 2026 | 11.59 | 11.76 | 11.22 | 11.30 | 253.07K |
| Aug 12, 2026 | 11.74 | 12.10 | 11.51 | 11.53 | 275.12K |
| Aug 11, 2026 | 11.18 | 12.27 | 11.02 | 11.78 | 456.08K |
| Aug 10, 2026 | 11.12 | 11.46 | 11.02 | 11.22 | 178.76K |
| Aug 07, 2026 | 11.63 | 11.98 | 10.75 | 11.27 | 214.66K |
| Aug 06, 2026 | 11.52 | 12.06 | 11.38 | 11.58 | 321.61K |
| Aug 05, 2026 | 11.15 | 11.74 | 10.58 | 11.59 | 548.57K |
| Aug 04, 2026 | 10.60 | 11.29 | 10.40 | 11.07 | 411.21K |
| Aug 03, 2026 | 10.00 | 10.81 | 9.90 | 10.76 | 571.75K |
| Jul 31, 2026 | 10.25 | 10.41 | 9.67 | 10.10 | 358.54K |
| Jul 30, 2026 | 10.00 | 10.59 | 10.00 | 10.43 | 230.81K |
| Jul 29, 2026 | 10.69 | 10.79 | 9.83 | 10.02 | 392.65K |
| Jul 28, 2026 | 10.30 | 10.64 | 9.97 | 10.53 | 355.52K |
| Jul 27, 2026 | 10.00 | 10.68 | 9.93 | 10.32 | 280.82K |
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
| Employees | 106 |
| Beta | 2.18 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |